iBio, Inc. (NYSEMKT:IBIO – Get Free Report)’s stock price rose 8.3% on Friday . The company traded as high as $2.35 and last traded at $2.35. Approximately 1,928,910 shares were traded during trading, an increase of 1,604% from the average daily volume of 113,212 shares. The stock had previously closed at $2.17.
iBio Price Performance
The company has a fifty day simple moving average of $1.61 and a 200-day simple moving average of $1.10. The company has a market cap of $60.71 million, a P/E ratio of -1.94 and a beta of 1.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.
About iBio
iBio, Inc is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.
The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases.
Read More
- Five stocks we like better than iBio
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
